Adicet Bio is a biopharmaceutical company discovering and developing allogeneic gamma delta T cell therapies for cancer. Co.'s product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptors (CAR) targeting CD20, is in Phase 1 study for the treatment of Non-Hodgkin's Lymphoma. Co.'s pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, Co. is engaged in preclinical stage activities directed to expansion of its pipeline of product candidates for both hematological malignancies and solid tumors. We show 50 historical shares outstanding datapoints in our coverage of ACET's shares outstanding history.
Understanding the changing numbers of ACET shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACET versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACET by allowing them to research ACET shares outstanding history
as well as any other stock in our coverage universe. |
Free ACET Email Alerts:
Video: Shares Outstanding Importance
